戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  postoperative complications (eg, pneumonia, pulmonary failure).
2 r postinfection lung healing, and subsequent pulmonary failure.
3  transfer), mediastinitis, advanced age, and pulmonary failure.
4 enous extracorporeal life support for severe pulmonary failure.
5 athogenesis of acute virus-induced shock and pulmonary failure.
6 ion for 17 months until death as a result of pulmonary failure.
7 ath was almost always secondary to end-stage pulmonary failure.
8 eptance as therapy for end-stage cardiac and pulmonary failure.
9  for neonates with pulmonary hypertension or pulmonary failure.
10 s innate defence mechanisms, predisposing to pulmonary failure.
11 of postoperative surgical site infection and pulmonary failure.
12 he use of pedicled flaps, mediastinitis, and pulmonary failure.
13 ion; two died early of toxicity; one died of pulmonary failure 17 months after transplantation (no ev
14 mics due to (1) ventricular dysfunction, (2) pulmonary failure, (3) pulmonary hypertension, or (4) a
15            Seventy-seven patients had either pulmonary failure alone (25 patients) or as a component
16 al agents, the patient developed progressive pulmonary failure and bacterial sepsis and died.
17        Fatal cases generally developed rapid pulmonary failure and one third were associated with bac
18                Early recognition of imminent pulmonary failure and rapid institution of ECLS are crit
19 had a rapid death characterized by fever and pulmonary failure and were identified from the autopsy f
20 ease, accompanied by clinical deterioration, pulmonary failure, and death.
21                     Chronic lung disease and pulmonary failure are complications that can occur after
22                       Among patients who had pulmonary failure as an indication for ECLS, the CNS com
23 isseminates and the animals develop a severe pulmonary failure, as demonstrated by lung mechanics and
24                     Combined acute renal and pulmonary failure has a very high mortality.
25 rse reactions to radiation and chemotherapy, pulmonary failure, immunodeficiency, glucose transporter
26 aves lives of patients with acute cardiac or pulmonary failure in a variety of clinical settings.
27 alization, AKI was associated with increased pulmonary failure, mechanical ventilation, pneumonia, my
28                   There were no instances of pulmonary failure, renal failure, stent-graft migration,
29 apeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patie
30              However, the DLM for predicting pulmonary failure was less effective with an ROC of 0.54
31       Severe ARDS was defined as acute onset pulmonary failure, with bilateral infiltrates on chest x